请选择一种语言

单击以下选项之一即表示您同意我们的 Cookie 政策隐私政策.


Please select a language

By clicking on one of options below you are agreeing to our Cookie Policy and Privacy Policy.

EN 中文

Areas of Focus

CSP has built an innovative, differentiated and late-stage pipeline of products, focused on rare disease and ophthalmology targeting indications with significant unmet needs in China

Rare disease

  • China is undergoing dramatic change from a market which ten years ago was broadly focussed on generic drugs to a market where patent protected innovative speciality products are becoming the norm
  • 1,423 rare diseases have been identified in China with 20 million rare disease patients with a market potential of $15.5bn USD
  • Currently however only about 20% of approved rare disease drugs by the US FDA are approved in China
  • Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval.
  • Reimbursement landscape is changing with 2/3 of approved rare disease products in China now being reimbursed. China are currently looking at new models to fund ultra-high cost medicines through commercial insurance plans

Ophthalmology

  • Ophthalmology is a huge opportunity and unmet need in China, where the ophthalmology market is growing at an average of around 17.5% a year
  • One third of the world’s blindness occurs in China and there is a government initiative to train more ophthalmologists over the next few years
  • Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval.
  • Abbreviated clinical development plans can be agreed leveraging clinical data generated in USA/ EU when there is unmet need in China